These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31183877)

  • 1. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
    Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
    Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of new myeloma agents on the transfusion laboratory.
    Jones AD; Moayeri M; Nambiar A
    Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
    Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
    Transfusion; 2024 Jul; 64(7):1217-1222. PubMed ID: 38767410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti-CD47 interference in red cell and platelet testing.
    Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
    Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
    Kim TY; Yoon MS; Hustinx H; Sim J; Wan HI; Kim H
    Transfusion; 2020 Oct; 60(10):2399-2407. PubMed ID: 32820530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
    Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
    Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
    [No Abstract]   [Full Text] [Related]  

  • 8. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
    Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
    Mei Z; Wool GD
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    Sikic BI; Lakhani N; Patnaik A; Shah SA; Chandana SR; Rasco D; Colevas AD; O'Rourke T; Narayanan S; Papadopoulos K; Fisher GA; Villalobos V; Prohaska SS; Howard M; Beeram M; Chao MP; Agoram B; Chen JY; Huang J; Axt M; Liu J; Volkmer JP; Majeti R; Weissman IL; Takimoto CH; Supan D; Wakelee HA; Aoki R; Pegram MD; Padda SK
    J Clin Oncol; 2019 Apr; 37(12):946-953. PubMed ID: 30811285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia patients with intensive chemotherapy.
    Byun JM; Park W; Shin DY; Koh Y; Kim I; Yoon SS; Park JH; Kim H; Hong J
    Blood Transfus; 2023 Nov; 21(6):479-487. PubMed ID: 37235735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion.
    Reyland L; Dwight M; Bullock T; Latham T; Lord K; Wardle A; Palmer D; Eggington J; Callaghan T; Seals D; Kulkarni S
    Transfus Med; 2020 Apr; 30(2):157-160. PubMed ID: 31914482
    [No Abstract]   [Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
    Swoboda DM; Sallman DA
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy and toxicity studies of a highly specific chimeric anti-CD47 antibody.
    Xu Z; Gao J; Yao J; Yang T; Wang D; Dai C; Ding Y
    FEBS Open Bio; 2021 Mar; 11(3):813-825. PubMed ID: 33449453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
    Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
    Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.